Dr. Michael M. Mikhail

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

Daniel Geynisman is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Geynisman is rated as an Elite provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

Philosophy of care | Personalized care starts during my first meeting with a patient and family. That's when I get to know the patient as completely as possible. I want to know about the patient's concerns, values and support system so I can provide care that is specific to him or her. | Also, I am a member of the skin and soft tissue cancer multidisciplinary consultation team. Together we review your diagnostic information and give you a written opinion reflecting the scope of your condition and recommendations for your best course of care. | Why I entered medicine | When I was young, I didn't like seeing doctors. It created a lot of anxiety for me. Now that I'm older, I can relate to the way people feel, especially when they're coping with the emotions caused by a serious condition like cancer. My grandmother died of uterine cancer in the 1960s. During her battle, I felt helpless. That is what attracted me to cancer research. Now I see the amazing progress we are making through cancer research. | Community involvement | I served on the state board of the American Cancer Society. Today, I take more of a grassroots approach to offer my support. I participate in events, such as 5K runs, that benefit charities. Dr. Nair is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Adult Soft Tissue Sarcoma, and Melanoma.